693P Preclinical activity of HLX43, a PD-L1 ... - Annals of Oncology
网页HLX43 showed promising efficacy and tolerability in preclinical assessments. It may offer a novel treatment for PD-1/PD-L1 inhibitor R/R cancers like NSCLC, HNSCC, ESCC, MEL, and OVC.
网页HLX43 is a novel antibody-drug conjugate that selectively delivers a toxin to PD-L1-expressing tumor cells. It shows excellent anti-tumor efficacy and low immunotoxicity in multiple PD-L1-positive CDX and PDX models, including breast, …
693P Preclinical activity of HLX43, a PD-L1 ... - Annals of Oncology
网页PD-1/PD-L1 monoclonal antibodies have revolutionised the landscape of cancer treatment. Nonetheless, some PD-L1+ patients do not respond to or become resistant to such therapy. The elevated expression of PD-L1 in tumours makes it an attractive target for ADC development, which could potentially alter the treatment for PD-1/PD-L1 inhibitor refractory/resistant (R/R) cancers.
Results From the Preclinical Study of HLX43, a Potential FIC
网页2023年10月24日 — HLX43 showed promising efficacy and safety results in our preclinical evaluation. This innovative novel PD-L1-targeting ADC has the potential to become a new treatment option for PD-1/PD-L1 inhibitor R/R cancers such as NSCLC, HNSCC, ESCA, SKCM and CRC. Our data warrant further development of HLX43 into the clinical setting. 参 …
693P Preclinical activity of HLX43, a PD-L1 ... - Semantic Scholar
网页2023年10月1日 — Semantic Scholar extracted view of "693P Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models" by Y. Shan et al.
网页HLX43 in rats and cynomolgus monkeys, with the maximum tolerated dose being 60 mg/kg in rats and 10 mg/kg in non-human primates. GLP toxicology studies will explore a higher dose at 20 mg/kg. Conclusions: HLX43 showed promising efficacy and tolerability in preclinical assess-ments.
复宏汉霖靶向PD-L1的ADC候选药物HLX43 I期研究完成首例受试者 …
网页2023年11月27日 — 本研究为一项评估HLX43在晚期/转移性实体瘤患者中的安全性、耐受性的开放、剂量递增、首次人体I期临床研究。研究将采用“3+3”方法，设计6个剂量水平（0.5 mg/kg、1 mg/kg、2 mg/kg、4 mg/kg、6 mg/kg、8 mg/kg），患者将接受不同水平的HLX43静脉输注给药，每三周一次。
ESMO 2023 | 潜在FIC PD-L1 ADC HLX43治疗晚期/转移性实体瘤的 …
网页2023年10月25日 — HLX43 showed promising efficacy and safety results in our preclinical evaluation. This innovative novel PD-L1-targeting ADC has the potential to become a new treatment option for PD-1/PD-L1 inhibitor R/R cancers such as NSCLC, HNSCC, ESCA, SKCM and CRC. Our data warrant further development of …
Henlius to Release the Preclinical Profiles of 2 ADC Programs at …
网页2023年9月21日 — HK) announced that the latest results of two ADC (Antibody-drug Conjugate) products, HLX42, the novel EGFR-targeting ADC, and HLX43, the PD-L1 targeting ADC, will be published as posters at the 2023 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain from October 20-24.
Henlius Receives the FDA IND Approval for Its PD-L1-Targeting …
网页2023年11月27日 — HLX43 is an antibody-drug conjugate (ADC) that targets programmed death-ligand 1 (PD-L1) and overcomes resistance to PD-1/L1 immunotherapies. Henlius announced the FDA approval of its IND application and the first dosing of a phase 1 trial for HLX43 in China.